- Gossamer Bio Inc GOSS announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).
- A mean difference in pulmonary vascular resistance (PVR) between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%, was observed in the study.
- An observed mean difference in six-minute walk distance (6MWD) between placebo and seralutinib of 6.5 meters numerically favored the seralutinib arm.
- Enhanced effects for both PVR and 6MWD were observed in patients with more severe baseline disease.
- Related: Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial.
- In FC III patients, a 21% reduction in PVR and 37m improvement in 6MWD were observed for the seralutinib arm vs. placebo.
- Seralutinib treatment resulted in a statistically significant reduction in NT-proBNP, a biomarker of right heart stress, as early as 12 weeks, increasing to a 408.3 ng/L mean difference from placebo at Week 24.
- Seralutinib was generally well tolerated in the TORREY study, with treatment-emergent adverse events (TEAEs) reported in 36 (86%) and 41 (93%) of the patients in the placebo and seralutinib arms, respectively.
- Price Action: GOSS shares are down 67.70% at $3.00 on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.